Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBITDA Margin % Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBITDA Margin % Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
EBITDA Margin %
32.33
18.16
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a EBITDA Margin % of 26.53% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. This is near median its historical median of 25.25. Over the past decade, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBITDA Margin % has ranged from 18.16 to 32.33. According to the industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #229 out of 961 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBITDA Margin % too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EBITDA Margin % of 26.53% is near median its 10-year median of 25.25. Over the past 10 years, this metric has ranged from a low of 18.16 to a high of 32.33. The Drug Manufacturers industry median EBITDA Margin % is 12.49. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 26.53% is 112.4% above this industry median. Based on the distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #229 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #229 out of 961 companies for EBITDA Margin %. This places El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 26.53% is 112.4% above this benchmark. Historically, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's own EBITDA Margin % has ranged from 18.16 to 32.33 over the past decade. While the company's 10-year median is 25.25 vs. the industry median of 12.49, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EBITDA Margin % of 26.53% is 112.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EBITDA Margin % is 26.53%, which is near median its own 10-year median of 25.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current EBITDA Margin % of 26.53%. The current EBITDA Margin % is 26.53%, which is near median its 10-year median of 25.25 and 112.4% above the Drug Manufacturers industry median of 12.49. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current EBITDA Margin % is 26.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Business Description
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
